[ad_1]

The latest sale reduced Walgreens’ ownership of AmerisourceBergen common stock from about 20% to about 17%, Walgreens said in its statement.

Walgreens also sold $2 billion of the company’s stock in early November, and it sold 6 million shares at $150 each in May, according to a statement, raising $900 million. The latest sell-off brings the total funds raised this year to nearly $4 billion.

Not a Modern Healthcare subscriber? Sign up today.

Walgreens held 52.9 million shares in AmerisourceBergen, a 25.5% stake, as of Aug. 2, according to data compiled by Bloomberg.

Walgreens said Thursday it would use the proceeds to both pay down debt and fund strategic priorities, including its definitive agreement for VillageMD to acquire Summit Health-CityMD for $9 billion.

Walgreens also said that the stock sales do not change the strategic partnership it has had with the drug wholesaler since 2013.

Walgreens’ international Chief Operating Officer Ornella Barra will continue to serve on AmerisourceBergen’s board of directors, the statement said.

This story first appeared in Crain’s Chicago Business.

[ad_2]

Source link

Leave a Reply

Explore More

Prescription drug use over a lifetime – Healthcare Economist

[ad_1] That is the topic of an interesting paper by Ho (2023). Prescription drug use has reached historic highs in the United States—a trend linked

Supreme Court to preserve abortion pill access for now

[ad_1] WASHINGTON — The Supreme Court on Friday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restrictions while a lawsuit continues. The

New Arizona law: Insurance must cover cancer biomarker tests

[ad_1] A bill signed into law by Arizona Gov. Doug Ducey on Friday requires health insurers and the state’s Medicaid plan to pay for so-called “biomarker tests” that are needed